Latest filing published 16 Sept 2026 for Alamar Biosciences, Inc..
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
The record of John L. Brottem opens on September 17, 2020 with a purchase of EUR 56,971 at Outset Medical, Inc., where Brottem is General Counsel. It is the only purchase on file, or 1% of open-market trades; it is followed by 71 sales worth EUR 4,063,210, with a median of EUR 35,264. The largest are EUR 251,401 on November 30, 2022, EUR 222,452 on February 15, 2022 and EUR 218,518 on January 18, 2022.
Of 115 filings published between September 17, 2020 and September 16, 2026, one concerns Alamar Biosciences, Inc. and 114 concern Outset Medical. The record also holds 31 option exercises and 12 grants. There were 33 filings in 2021, 28 in 2022 and 25 in 2023, against 10 in 2024. Eight filings, 6 of them sales, fall in the last twelve months, with a median publication delay of 1 day.
At Outset Medical, 71 of Brottem's own market trades fall within 30 days of a trade by Leslie Trigg, all on the same side. Nabeel Ahmed follows (45, of which 42 on the same side), then Martin Vazquez (43), Stacey L. Porter (30) and Steven S. Williamson (28).
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 115 declarations